Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.
Article
CAS
PubMed
Google Scholar
Wolfe F. The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic. Am J Med. 1997;103(6a):12s–8s.
Article
CAS
PubMed
Google Scholar
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–81.
Article
CAS
PubMed
Google Scholar
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. Jama. 1999;282(22):2131–5.
Article
CAS
PubMed
Google Scholar
Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease activity score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66(9):1221–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761–9.
Article
CAS
PubMed
Google Scholar
Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64(12):1731–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155–63.
Article
CAS
PubMed
Google Scholar
van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50(3):709–15.
Article
PubMed
CAS
Google Scholar
Armas-Gonzalez E, Dominguez-Luis MJ, Diaz-Martin A, Arce-Franco M, Castro-Hernandez J, Danelon G, et al. Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. Arthritis Res Ther. 2018;20(1):114.
Article
PubMed
PubMed Central
CAS
Google Scholar
Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid Synovium. PLoS Med. 2009;6(1):e1.
Article
PubMed
PubMed Central
Google Scholar
Mandik-Nayak L, Huang G, Sheehan KC, Erikson J, Chaplin DD. Signaling through TNF receptor p55 in TNF-alpha-deficient mice alters the CXCL13/CCL19/CCL21 ratio in the spleen and induces maturation and migration of anergic B cells into the B cell follicle. J Immunol. 2001;167(4):1920–8.
Article
CAS
PubMed
Google Scholar
Wengner AM, Hopken UE, Petrow PK, Hartmann S, Schurigt U, Brauer R, et al. CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum. 2007;56(10):3271–83.
Article
CAS
PubMed
Google Scholar
Pandya JM, Lundell AC, Andersson K, Nordstrom I, Theander E, Rudin A. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. Arthritis Res Ther. 2017;19(1):20.
Article
PubMed
PubMed Central
CAS
Google Scholar
Moura RA, Quaresma C, Vieira AR, Goncalves MJ, Polido-Pereira J, Romao VC, et al. B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. PLoS One. 2017;12(9):e0182927.
Article
PubMed
PubMed Central
CAS
Google Scholar
Han BK, Kuzin I, Gaughan JP, Olsen NJ, Bottaro A. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study. Arthritis Res Ther. 2016;18:93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kumagai S, Uemura Y, Saito T, Umeda R, Muta A, Izumi M, et al. AB0240 MMP-3 as A Biomarker of Disease Activity of Rheumatoid Arthritis. Ann Rheum Dis. 2016;75(Suppl 2):980.
Article
Google Scholar
Loza M, Sweet K, Peffer N, Franks C, Ma K, Campbell K, Sims M, Dasgupta B. Consistent Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). https://acrabstracts.org/abstract/consistent-pharmacodynamic-effects-of-sirukumab-an-anti-il-6-cytokine-monoclonal-antibody-on-serumanalytes-across-four-phase-3-clinical-trials-in-rheumatoid-arthritis/. Accessed Aug 20 2020.
Bugatti S, Vitolo B, Benaglio F, Montecucco C, Caporali R, Manzo A. A5.14 serum CXCL13 is a non-invasive synovitis marker holding non-redundant information compared with acute phase reactants and autoantibodies in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(Suppl 1):A46–A7.
Article
Google Scholar
Han JH, Suh CH, Jung JY, Nam JY, Kwon JE, Yim H, et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease. Arthritis Res Ther. 2015;17:260.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yeo L, Scheel-Toellner D, Ludwig C, Sahbudin I, Juarez M, Buckley C, Raza K, Filer A. Synovial Ultrasound Power Doppler Enhancement Reflects Multiple Cytokine Expression in Synovial Tissue, Distinguishing Distinct High Macrophage-Associated and Low Inflammation Profiles [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). https://acrabstracts.org/abstract/synovial-ultrasound-power-doppler-enhancement-reflects-multiple-cytokine-expression-insynovial-tissue-distinguishing-distinct-high-macrophage-associated-and-low-inflammation-profiles/. Accessed Aug 20 2020.
Bugatti S, Manzo A, Vitolo B, Benaglio F, Binda E, Scarabelli M, et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology (Oxford). 2014;53(10):1886–95.
Article
CAS
Google Scholar
Greisen SR, Schelde KK, Rasmussen TK, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity. Arthritis Res Ther. 2014;16(5):434.
Article
PubMed
PubMed Central
CAS
Google Scholar
Bugatti S, Manzo A, Vitolo B, Benaglio F, Binda E, Scarabelli M, et al. THU0546 Serum CXCL13 as A Biomarker of Disease Activity and Severity in IN Rheumatoid Arthritis. Comparison with Acute Phase Reactants and the Autoantibody Profile. Ann Rheum Dis. 2014;73(Suppl 2):371.
Article
Google Scholar
Moura RA, Canhão H, Polido-Pereira J, Navalho M, Leandro MJ, Cambridge G, et al. AB0085 Serum Levels of CXCL13 Are Increased in Untreated Patients with Rheumatoid Arthritis from the First Weeks of Disease Development. Ann Rheum Dis. 2014;73(Suppl 2):832.
Article
Google Scholar
Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, et al. Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res Ther. 2014;16(2):R103.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, et al. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65(9):2253–61.
Article
CAS
PubMed
Google Scholar
Sherif NM, Arafa MM, Ibrahim SE, Moussa SG. CXC ligand 13 in rheumatoid arthritis and its relation to secondary Sjögren’s syndrome. Egypt Rheumatol. 2013;35(3):121–6.
Article
Google Scholar
Fathi Ahmed S, Badr T, Hosny SM, Hamayed HFA. Assessment of synovitis in early rheumatoid arthritis by CXCL13 serum levels and power Doppler ultrasonography: correlation with disease activity. Egypt Rheumatol. 2013;35(1):21–7.
Article
Google Scholar
Setiadi FL-K, N. Kummerfeld S, Choy DF, CTJ H, Fischer S, et al. Synovial Subset–Derived Baseline Serum Biomarkers Segregate Rheumatoid Arthritis Patients Into Subgroups With Distinct Serum Protein and Clinical Characteristics. Arthritis Rheum. 2013;65:S552–3 2013.
Google Scholar
Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, et al. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther. 2012;14(1):R34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum. 2011;63(5):1265–73.
Article
CAS
PubMed
Google Scholar
Rinaldi MVBT, Van Roy M, Bontinck L, Hohlbaum A, Snoeck V, Dombrecht E, Van Beneden K, Schoen P, Ulrichts H. Assessment of dose dependent effects of Vobarilizumab, an anti-IL6 receptor (IL-6R) Nanobody®, on systemic biomarkers in patients with moderate-to-severe rheumatoid arthritis (RA): results of two phase 2b studies [abstract]. Arthritis Rheum. 2017;69(suppl 10):2017.
Google Scholar
Bugatti S, Manzo A, Vitolo B, Benaglio F, Caporali R, Montecucco C. SAT0087 Serum Levels of CXCL13 Refine The Predictive Ability of Autoantibodies To Identify Unstable Remission in Early Rheumatoid Arthritis. Ann Rheum Dis. 2016;75(Suppl 2):696.
Article
Google Scholar
de Jong TD, Vosslamber S, de Jager W, Raterman H, Voskuyl AE, Gelderman KA, et al. A1.7 Serum cytokine changes in rituximab-treated rheumatoid arthritis patients. Ann Rheum Dis. 2014;73(Suppl 1):A3 A.
Google Scholar
El-Sherbiny YM, Churchman S, Emery P, Vital EM, Ponchel F. A5.18 Impact of Rituximab on Synovial Gene Expression. Ann Rheum Dis. 2013;72(Suppl 1):A37 A.
Article
Google Scholar
Taylor PC, Galien R, Van der Aa A, Jamoul C, Harrison P, Tasset C, Pan Y, Goyal L, Li W, Tarrant J. Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). https://acrabstracts.org/abstract/monotherapy-with-filgotinib-a-jak1-selective-inhibitor-reduces-disease-related-biomarkers-in-rheumatoid-arthritis-patients/. Accessed Aug 20 2020.
Gabay CMJ, Daskalakis N, Barbot A, Zilberstein M, Boyapati A. Effect of Sarilumab on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors [abstract]. Arthritis Rheum. 2016;68(suppl 10):2016.
Google Scholar
Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311–6.
Article
CAS
PubMed
Google Scholar
Dennis G Jr, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16(2):R90.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (the ALTARA study). Arthritis Res Ther. 2014;16(5):467.
Article
PubMed
PubMed Central
CAS
Google Scholar
Herman A, Musselman D, Fischer S, Setiadi A, Gabay C, Kavanaugh A, et al. THU0130 Distinct Biomarkers Enrich for Clinical Response to Tocilizumab (TCZ) and Adalimumab (ADA) in Adacta: A Head-to-Head Monotherapy Study in Patients (PTS) with Methotrexate (MTX)-IR Rheumatoid Arthritis (RA). Ann Rheum Dis. 2013;72(Suppl 3):A206 A.
Google Scholar
Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin alpha: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther. 2012;14(1):R6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(3):603–10.
Article
CAS
Google Scholar
van Baarsen LGM, Bos CL, van der Pouw KTCTM, Verweij CL. Transcription profiling of rheumatic diseases. Arthritis Res Ther. 2009;11(1):207.
Article
PubMed
PubMed Central
CAS
Google Scholar